Results 91 to 100 of about 1,190,584 (342)

Afatinib treatment in advanced non-small cell lung cancer

Lung Cancer: Targets and Therapy, 2011
Jane L Hurwitz, Paula Scullin, Lynn CampbellDepartment of Medical Oncology, Northern Ireland Cancer Centre, Belfast, UKAbstract: Despite some recent advances in the management of advanced non-small cell lung cancer (NSCLC), prognosis for these patients ...
Hurwitz JL, Scullin P, Campbell L
doaj  

Molecular pathways and therapeutic targets in lung cancer [PDF]

, 2014
Lung cancer is still the leading cause of cancer death worldwide. Both histologically and molecularly lung cancer is heterogeneous. This review summarizes the current knowledge of the pathways involved in the various types of lung cancer with an emphasis
Bueno, Raphael, Dennis, Phillip A., Hensing, Thomas, Otterson, Gregory A., Salgia, Ravi, Shtivelman, Emma, Simon, George R.   +6 more
core   +2 more sources

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

Phase II study of ACNU in non-small-cell lung cancer: EORTC study 08872 [PDF]

, 1991
A total of 62 patients with metastatic or locally advanced non-small-cell lung cancer were entered in a phase II study of ACNU. Initially, the drug was given i. v.
Ardizzoni, A. (A.), Dalesio, O. (O.), Estapé, J. (J.), Giaccone, G. (Giuseppe), Kirkpatrick, A. (A.), Mcvie, J.G. (John Gordon), Planting, A.S.Th. (André), Scagliotti, G.V. (Giorgio), Splinter, T.A.W. (Ted)   +8 more
core   +2 more sources

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

MET Inhibition in Non-Small Cell Lung Cancer

European Medical Journal, 2019
Cancer treatment paradigms have evolved over recent years with an emphasis on personalised medicine. Targeted agents are being used to improve treatment outcomes and quality of life.
Shabnam Rehman, Grace K. Dy
doaj  

Long noncoding nature brain-derived neurotrophic factor antisense is associated with poor prognosis and functional regulation in non–small cell lung caner

Tumor Biology, 2017
In this study, we evaluated the prognostic potential and functional regulation of human nature antisense, brain-derived neurotrophic factor antisense, in non–small cell lung cancer.
MingJing Shen, Zhonghua Xu, Kanqiu Jiang, Weihua Xu, Yongbin Chen, ZhongHeng Xu   +5 more
doaj   +1 more source

Systemic treatment of non-small cell lung cancer brain metastases

Contemporary Oncology, 2016
In the systemic treatment of brain metastases from non-small cell lung cancer (BMF-NSCLC) chemo- and targeted therapy are used. Response rates after platinum-based chemotherapy, range from 23% to 45%.
Ida Cedrych, Maksymilian A. Kruczała, Tomasz Walasek, Jerzy Jakubowicz, Paweł Blecharz, Marian Reinfuss   +5 more
doaj   +1 more source

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer [PDF]

, 2019
Bo Gong, Kazuma Kiyotani, Seiji Sakata, Seiji Nagano, Shun Kumehara, Satoko Baba, Benjamin Besse, Noriko Yanagitani, Luc Friboulet, Makoto Nishio, Kengo Takeuchi, Hiroshi Kawamoto, Naoya Fujita, Ryohei Katayama   +13 more
openalex   +1 more source

KRASQ61H Preferentially Signals through MAPK in a RAF Dimer-Dependent Manner in Non–Small Cell Lung Cancer [PDF]

, 2020
Zhi-Wei Zhou, Chiara Ambrogio, Asim K. Bera, Qing Li, Xing-Xiao Li, Lianbo Li, Jieun Son, Sudershan Reddy Gondi, Jiaqi Li, Emily Campbell, Hua Jin, Jeffrey J. Okoro, Cheng‐Xiong Xu, Pasi A. Jänne, Kenneth D. Westover   +14 more
openalex   +1 more source